Abstract
Cell migration and angiogenesis are key steps in tumor metastasis. However, the mechanism of migration regulated by vascular endothelial growth factor (VEGF), a potent regulator of angiogenesis, is not completely understood. This study examined the relationship between VEGF and migration, along with the mechanism involved in the VEGF-regulated migration of human gastric cancer cells. The level of cell migration was increased by recombinant human (rh)VEGF-165 in the VEGF receptor-2-expressing SNU-601 cells. Interleukin (IL)-18 is associated with the malignant progression of tumors. Accordingly, this study examined the effect of IL-18 on the migration of cancer cells in order to identify the factors involved in VEGF-enhanced migration. Inhibiting IL-18 markedly reduced the level of VEGF-enhanced migration, and IL-18 increased cell migration directly through filamentous-actin polymerization and tensin downregulation. It was confirmed that rhVEGF-165 increased IL-18 production significantly. An antioxidant and an extracellular signal-regulated kinase (ERK)1/2-specific inhibitor blocked rhVEGF-165-enhanced IL-18 production. Accordingly, rhVEGF-165 increased the generation of region of interest (ROI) and activated the ERK1/2 pathway. These results suggest that rhVEGF-165 enhances IL-18 production via the generation of ROI and ERK1/2 phosphorylation, which results in the increased migration of gastric cancer cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cao R, Farnebo J, Kurimoto M, Cao Y . (1999). Interleukin-18 acts as an angiogenensis and tumor suppressor. FASEB J 13: 2195–2202.
Carmeliet P, Jain RK . (2000). Angiogenesis in cancer and other diseases. Nature 407: 249–257.
Carrascal MT, Mendoza L, Valcarcel M, Salado C, Egilegor E, Telleria N et al. (2003). Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res 63: 491–497.
Chen J, De S, Brainard J, Byzova TV . (2004). Metastatic properties of prostate cancer cells are controlled by VEGF. Cell Commun Adhes 11: 1–11.
Cho D, Kang JS, Park JH, Kim YI, Hahm E, Lee J et al. (2002). The enhanced IL-18 production by UVB irradiation requires ROI and AP-1 signaling in human keratinocyte cell line (HaCaT). Biochem Biophys Res Commun 298: 289–295.
Cho D, Song H, Kim YM, Houh D, Hur DY, Park H et al. (2000). Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res 60: 2703–2709.
Cumberbatch M, Dearman RJ, Antonopoulos C, Groves RW, Kimber I . (2001). Interleukin-18 induces Langerhans cell migration by a tumor necrosis factor-alpha- and IL-1beta-dependent mechanism. Immunology 102: 323–330.
Gossart S, Cambon C, Orfila C, Seguelas MH, Lepert JC, Rami J et al. (1996). Reactive oxygen intermediates as regulators of TNF-alpha production in rat lung inflammation induced by silica. J Immunol 156: 1540–1548.
Horwitz AR, Parsons JT . (1999). Cell migration — movin' on. Science 286: 1102–1103.
Ishida Y, Migita K, Izumi Y, Nakao K, Ida H, Kawakami A et al. (2004). The role of IL-18 in the modulation of matrix metalloproteinases and migration of human natural killer (NK) cells. FEBS Lett 569: 156–160.
Ju DW, Tao Q, Lou G, Bai M, He L, Yang Y et al. (2001). Interleukin-18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates. Cancer Res 61: 3735–3740.
Lissoni P, Brivio F, Rovelli F, Fumagalli G, Malugani F, Vaghi M et al. (2000). Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease. J Biol Regul Homeost Agents 14: 275–277.
Lo SH . (2004). Tensin. Int J Biochem Cell Biol 36: 31–34.
Lo SH, Janmey PA, Hartwig JH, Chen LB . (1994). Interactions of tensin with actin and identification of its three distinct actin-binding domain. J Cell Biol 125: 1067–1075.
Majima T, Ichikura T, Chochi K, Kawabata T, Tsujimoto H, Sugasawa H et al. (2006). Exploitation of interleukin-18 by gastric cancers for growth and evasion of host immunity. Int J Cancer 118: 388–395.
Meili R, Firtel RA . (2003). Two poles and a compass. Cell 114: 153–156.
Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T et al. (1995). Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378: 88–91.
Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE . (2001). Evidence of IL-18 as a novel angiogenic mediator. J Immunol 167: 1644–1653.
Pedram A, Razandi M, Levin ER . (1998). Extracellular signal-regulated protein kinase/Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem 273: 26722–26728.
Stoll S, Muller G, Kurimoto M, Saloga J, Tanimoto T, Yamauchi H et al. (1997). Production of IL-18 (IFN-gamma-inducing factor) messenger RNA and functional protein by murine keratinocytes. J Immunol 159: 298–302.
Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM . (1995). Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55: 3964–3968.
Udagawa N, Horwood NJ, Elliott J, Mackay A, Owens J, Okamura H et al. (1997). Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med 185: 1005–1012.
Vidal-Vanaclocha F, Fantuzzi G, Mendoza L, Fuentes AM, Anasagasti MJ, Martin J et al. (2000). IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci USA 97: 734–739.
Zhang B, Wu KF, Cao ZY, Rao Q, Ma XT, Zheng GG et al. (2004). IL-18 increases invasiveness of HL-60 myeloid leukemia cells: up-regulation of matrix metalloproteinase-9 (MMP-9) expression. Leukemia Res 28: 91–95.
Zhang H, Wu J, Meng L, Shou CC . (2002). Expression of vascular endothelial growth factor and its receptor KDR and Flt-1 in gastric cancer cells. World J Gastroenterol 8: 994–998.
Acknowledgements
This work was supported by the Korea Science & Engineering Foundation (KOSEF) through the Tumor Immunity Medical Research Center (TIMRC) at Seoul National University College of Medicine and through the Research Center for Women's Disease (RCWD; SRC program (R11-2005-017-02003-0)) at Sookmyung Women's University.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Kim, KE., Song, H., Kim, T. et al. Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines. Oncogene 26, 1468–1476 (2007). https://doi.org/10.1038/sj.onc.1209926
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209926
Keywords
This article is cited by
-
Pyroptosis: mechanisms and diseases
Signal Transduction and Targeted Therapy (2021)
-
The role of microenvironment in tumor angiogenesis
Journal of Experimental & Clinical Cancer Research (2020)
-
Effects of interleukin-18 promoter (C607A and G137C) gene polymorphisms and their association with oral squamous cell carcinoma (OSCC) in northern India
Tumor Biology (2014)
-
Genes of the Interleukin-18 Pathway Are Associated With Susceptibility to Barrett's Esophagus and Esophageal Adenocarcinoma
American Journal of Gastroenterology (2012)